» Articles » PMID: 39816097

A Network Pharmacology Approach to Elucidate the Anti-inflammatory and Antioxidant Effects of Bitter Leaf ( Del.)

Overview
Journal Narra J
Date 2025 Jan 16
PMID 39816097
Authors
Affiliations
Soon will be listed here.
Abstract

The therapeutic potential of bitter leaf ( Del.) has been established both empirically and in various scientific investigations. However, the molecular pathways related to its possible anti-inflammatory and antioxidant properties remain unclear. Therefore, the aim of this study was to elucidate the molecular interactions between bitter leaf's bioactive compounds and cellular targets involved in these activities. The compounds in bitter leaf were identified using gas chromatography-mass spectrometry (GC-MS) analysis, and subsequently, a network pharmacology approach was employed together with molecular docking and dynamics simulations. Acetonitrile (4.5%) and dimethylamine (4.972%) were the most prevalent compounds among the 38 identified by the GC-MS analysis of bitter leaf extract. The proto-oncogene tyrosine-protein kinase (SRC) demonstrated significant connectivity within the antioxidant network, highlighting its pivotal role in facilitating inter-protein communication. It also exhibited strategic positioning in anti-inflammatory mechanisms based on closeness centrality (0.385). The enrichment analysis suggested multifaceted mechanisms of bitter leaf compounds, including transcriptional regulation and diverse cellular targeting, indicating broad antioxidant and anti-inflammatory effects. Eicosapentaenoyl ethanolamide (EPEA) displayed strong interactions with multiple proteins, including SRC (-7.17 kcal/mol) and CYPA (-6.88 kcal/mol). Moreover, EPEA demonstrated to form a stable interaction with SRC during a 100 ns simulation. In conclusion, the computational simulations revealed that the hypothetical antioxidant and anti-inflammatory actions of bitter leaf compounds were achieved by specifically targeting SRC. However, confirmation using either in vitro or in vivo techniques is necessary.

References
1.
Rebe C, Ghiringhelli F . STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers (Basel). 2019; 11(9). PMC: 6770459. DOI: 10.3390/cancers11091280. View

2.
Sherman B, Hao M, Qiu J, Jiao X, Baseler M, Lane H . DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-W221. PMC: 9252805. DOI: 10.1093/nar/gkac194. View

3.
Zhao M, Wu F, Tang Z, Yang X, Liu Y, Wang F . Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis. Front Pharmacol. 2023; 14:1256946. PMC: 10568483. DOI: 10.3389/fphar.2023.1256946. View

4.
Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J . CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011; 286(20):17543-59. PMC: 3093829. DOI: 10.1074/jbc.M110.198515. View

5.
Hussain M, Ikram W, Ikram U . Role of c-Src and reactive oxygen species in cardiovascular diseases. Mol Genet Genomics. 2023; 298(2):315-328. DOI: 10.1007/s00438-023-01992-9. View